A Glimpse Into The Expert Outlook On Pacific Biosciences Through 4 Analysts
Portfolio Pulse from Benzinga Insights
Recent analyst ratings for Pacific Biosciences (NASDAQ:PACB) show a mix of bullish and indifferent sentiments, with a notable decrease in the average 12-month price target from $10.38 to $6.12, a 41.04% drop. Analysts from TD Cowen, Barclays, Goldman Sachs, and UBS have lowered their price targets, reflecting adjustments based on market conditions and company performance. Despite challenges in market capitalization, revenue growth, net margin, ROE, ROA, and debt management, Pacific Biosciences has shown a significant revenue growth rate of 113.35% as of December 31, 2023.
April 17, 2024 | 8:00 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Pacific Biosciences faces a mixed analyst outlook with lowered price targets, yet reports a significant revenue growth. Financial challenges persist in profitability and debt management.
The mixed analyst ratings and significant drop in the average price target suggest uncertainty, which could lead to short-term volatility in PACB's stock price. However, the impressive revenue growth indicates underlying business strength, potentially mitigating negative impacts. The financial challenges highlighted, such as a high debt-to-equity ratio and below-average profitability metrics, may concern investors, but the revenue growth could offset these concerns to some extent.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100